HealthcareServices

Neuroblastoma Market Size and Growth Forecast for Businesses 2025–2029

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Neuroblastoma Market?

The neuroblastoma market size has exhibited robust growth over recent years. Forecasts suggest an increase from $2.97 billion in 2024 to $3.14 billion in 2025, at a compound annual growth rate (CAGR) of 5.7%. This historical expansion is attributable to several factors, including a rise in neuroblastoma prevalence, heightened research and development for pediatric neuroblastoma treatments, an increasing incidence of childhood cancer, and growing governmental funding and support.

The neuroblastoma market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.91 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.6%. Key factors contributing to this projected growth include a rise in government funding, a higher incidence of the disease, a stronger emphasis on early detection, the increasing occurrence of genetic mutations, and advancements in research and understanding. Significant trends anticipated during this period encompass the creation of drugs that target specific molecular pathways, breakthroughs in non-invasive imaging technologies, progress in gene-editing technologies, a greater emphasis on individualized treatment approaches, and the formulation of radiolabeled compounds.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp

What Are The Drivers Pushing New Developments In The Neuroblastoma Market?

The escalating occurrence of childhood cancer is anticipated to drive expansion within the neuroblastoma market in the coming years. Childhood cancer encompasses various malignancies primarily affecting children and adolescents, frequently impacting organs such as the brain, blood, and bones, thus requiring specialized treatment methods. This rise in childhood cancer incidence is attributed to several factors including improved diagnostic techniques, greater awareness, environmental exposures, genetic predispositions, and advancements in medical research. Neuroblastoma treatment delivers targeted therapies for childhood cancer, facilitating early and effective intervention which reduces the risk of recurrence and improves outcomes for young patients. For instance, in May 2024, as per the American Cancer Society, a US-based professional organization company, around 9,620 children under the age of 15 in the United States are projected to be diagnosed with cancer in 2024, an increase from 5,290 cases in 2023. Hence, the increasing incidence of childhood cancer is fueling the growth of the neuroblastoma market.

What Are The Key Segments In The Neuroblastoma Market?

The neuroblastomamarket covered in this report is segmented –

1) By Product Types: Tablets; Vaccines; Other Product Types

2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types

3) By Distribution Channel: Online; Offline

4) By End-User: Hospitals; Clinics

Subsegments:

1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets

2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines

3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products

What Long-Term Trends Will Shape The Future Growth Of The Neuroblastoma Industry?

Major companies within the neuroblastoma market are focusing on the creation of advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target and treat cancer cells. A humanized anti-GD2 monoclonal antibody is engineered to identify the GD2 molecule on cancer cells, incorporating human components to reduce immune rejection. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is specifically designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. Under the agreement’s terms, Renaissance has secured exclusive rights for the development, manufacturing, and commercialization of Hu14.18 across significant global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

Which Leading Players Are Enhancing Their Neuroblastoma Market Presence Worldwide?

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neuroblastoma–global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Neuroblastoma Market?

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neuroblastoma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp

Browse Through More Reports Similar to the Global Neuroblastoma Market 2025, By The Business Research Company

Neuroprosthetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Antibodies And Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroscience-antibodies-and-assays-global-market-report

Neuroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795